Last reviewed · How we verify
carbetocin 100 µg
Carbetocin 100 µg, marketed by Oslo University Hospital, is a drug with a key composition patent expiring in 2028. The drug's market position and primary indication are not specified, but it holds a unique mechanism of action that may offer a competitive edge. The primary risk is the patent expiry in 2028, which could lead to increased competition from generics.
At a glance
| Generic name | carbetocin 100 µg |
|---|---|
| Also known as | Pabal, injection |
| Sponsor | Oslo University Hospital |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Carbetocin Myocardium Trial 2014 Part 2 (PHASE4)
- The Clinical Carbetocin Myocardium Trial (PHASE4)
- Carbetocin Versus Oxytocin and Ergometrine for the Prevention of Postpartum Hemorrhage (NA)
- Carbetocin Versus Syntometrine in Obese Women Undergoing Elective Cesarean (PHASE4)
- Haemodynamic and Cardiovascular Effects of Carbetocin and Oxytocin (NA)
- Carbetocin Versus Oxytocin and Hemodynamic Effects (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- carbetocin 100 µg CI brief — competitive landscape report
- carbetocin 100 µg updates RSS · CI watch RSS
- Oslo University Hospital portfolio CI